한국유니온제약, 최대주주 부광약품으로 변경

Korean Union Pharma's controlling shareholder shifted from Park Kwang-seok to Bugwang Pharma through a rights offering tied to court-approved restructuring, with Bugwang acquiring 75.14% stake using KRW 30 billion in capital. This ownership transition marks a critical inflection point where the financially troubled company's direction will now be steered by new management, potentially enabling debt repayment and operational turnaround under fresh strategic leadership.